[Congressional Record Volume 167, Number 145 (Tuesday, August 10, 2021)]
[Senate]
[Page S6409]
From the Congressional Record Online through the Government Publishing Office [www.gpo.gov]

  SA 3772. Ms. WARREN submitted an amendment intended to be proposed by 
her to the concurrent resolution S. Con. Res. 14, setting forth the 
congressional budget for the United States Government for fiscal year 
2022 and setting forth the appropriate budgetary levels for fiscal 
years 2023 through 2031; which was ordered to lie on the table; as 
follows:

       At the end of title III, add the following:

     SEC. 3___. DEFICIT-NEUTRAL RESERVE FUND RELATING TO 
                   INCREASING NATIONAL CAPACITY TO DOMESTICALLY 
                   MANUFACTURE ACTIVE PHARMACEUTICAL INGREDIENTS 
                   AND STARTING MATERIALS FOR DRUGS CRITICAL TO 
                   PUBLIC HEALTH.

       The Chairman of the Committee on the Budget of the Senate 
     may revise the allocations of a committee or committees, 
     aggregates, and other appropriate levels in this resolution, 
     and make adjustments to the pay-as-you-go ledger, for one or 
     more bills, joint resolutions, amendments, amendments between 
     the Houses, motions, or conference reports relating to 
     increasing national capacity to domestically manufacture 
     active pharmaceutical ingredients and starting materials for 
     drugs critical to public health, by the amounts provided in 
     such legislation for those purposes, provided that such 
     legislation would not increase the deficit over either the 
     period of the total of fiscal years 2022 through 2026 or the 
     period of the total of fiscal years 2022 through 2031.
                                 ______